• Clinical Evidence

Goal Range Effect on Hypoglycemia Incidence for Intravenous Insulin Dosing

Setting: Cohort of five unaffiliated acute care hospitals.

Objective

This retrospective study examines the effect of goal range on incidence of hypoglycemia in patients receiving intravenous insulin therapy (managed with EndoTool).

Setting

Cohort of five unaffiliated acute care hospitals.

Results

  • Incidence of hypoglycemia <70 mg/dL was 35.5% lower with a goal range of 160-200 mg/dL goal range than a goal range of 100-140 mg/dL (0.22% vs 0.34% of blood glucose readings).
  • Whereas 73% of hypoglycemia events occurred following a blood glucose <120 mg/dL, 27% occurred following a blood glucose >120 mg/dL.

Conclusions

With use of EndoTool to manage intravenous insulin therapy, incidence of hypoglycemia may likely decrease by reducing the overall goal range spread concurrent to reducing the upper limit.
Objective

This retrospective study examines the effect of goal range on incidence of hypoglycemia in patients receiving intravenous insulin therapy (managed with EndoTool).

Setting

Cohort of five unaffiliated acute care hospitals.

Results
  • Incidence of hypoglycemia <70 mg/dL was 35.5% lower with a goal range of 160-200 mg/dL goal range than a goal range of 100-140 mg/dL (0.22% vs 0.34% of blood glucose readings).
  • Whereas 73% of hypoglycemia events occurred following a blood glucose <120 mg/dL, 27% occurred following a blood glucose >120 mg/dL.
Conclusions

With use of EndoTool to manage intravenous insulin therapy, incidence of hypoglycemia may likely decrease by reducing the overall goal range spread concurrent to reducing the upper limit.

References

Authors

Anderson Schrader; W. Patrick Burgess; Laurel Fuqua.

Source

Presented at American Association of Clinical Endocrinologists Scientific & Clinical Congress.

Year

2019

Quick navigation
Objective
Setting
Results
Conclusions
References
Objective

This retrospective study examines the effect of goal range on incidence of hypoglycemia in patients receiving intravenous insulin therapy (managed with EndoTool).

Setting

Cohort of five unaffiliated acute care hospitals.

Results
  • Incidence of hypoglycemia <70 mg/dL was 35.5% lower with a goal range of 160-200 mg/dL goal range than a goal range of 100-140 mg/dL (0.22% vs 0.34% of blood glucose readings).
  • Whereas 73% of hypoglycemia events occurred following a blood glucose <120 mg/dL, 27% occurred following a blood glucose >120 mg/dL.
Conclusions

With use of EndoTool to manage intravenous insulin therapy, incidence of hypoglycemia may likely decrease by reducing the overall goal range spread concurrent to reducing the upper limit.

References

Authors

Anderson Schrader; W. Patrick Burgess; Laurel Fuqua.

Source

Presented at American Association of Clinical Endocrinologists Scientific & Clinical Congress.

Year

2019

Short and Sweet Headlines are Best!

Related posts

Image
  • Clinical Evidence

Near Elimination of Severe Hypoglycemia with EndoTool IV Across a 19-Hospital Health System

Near Elimination of Severe Hypoglycemia with EndoTool IV Across a 19-Hospital Health System

To evaluate the impact of EndoTool IV insulin dosing software on reducing severe hypoglycemia (SH) (blood glucose < 40 mg/dL) across 19-hospitals at a prominent health system, including outcomes in patients with renal insufficiency.
Image
  • Clinical Evidence

Temple Health Achieves Zero Severe Hypoglycemia in Renally Impaired Patients with EndoTool SubQ

Temple Health Achieves Zero Severe Hypoglycemia in Renally Impaired Patients with EndoTool SubQ

To evaluate the safety and efficacy of the EndoTool SubQ (ETSQ) insulin dosing application for subcutaneous (SQ) insulin administration in hospitalized patients, and to compare clinical outcomes against those treated using a standard insulin order set. The analysis also examined performance in high-risk patients with advanced renal impairment.
Image
  • Clinical Evidence

Improving Inpatient Glycemic Safety at Temple Health with EndoTool SubQ

Improving Inpatient Glycemic Safety at Temple Health with EndoTool SubQ

Temple Health, a 3-hospital academic system was experiencing high rates of hypoglycemia due to reliance on sliding scale insulin (SSI). To improve safety and align with ADA guidelines, the hospital implemented EndoTool SubQ, a patient-specific insulin dosing software the supports four dosing protocols, including basal-bolus-correction (BBC).
Get in Touch

Ready to get started?

Fill in your details and one of our friendly team members will be in touch to show you how easily EndoTool can support your hospital.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Name*
By submitting this form, you consent to the processing of your personal information, including sensitive personal information you provide, in accordance with the Monarch Medical Technologies Privacy Notice.